Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... physicians in achieving better outcomes for AF, ... venous thromboembolism patients, INDIANAPOLIS, March 19 ... equipment and supplies for all long-term,warfarin users who monitor their own ... System for Patient Self-Testing. This,expansion opens the door to increased patient ...
... (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced ... patients with Type 1 diabetes,in a Phase 2 ... TPM/Insulin. The lead clinical investigators of the trial ... Royal Brisbane and,Women,s Hospital, and William Hsu, who ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 2Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 3Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 4Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 2Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 3
(Date:4/22/2014)... for low-income patients may ease the financial burden ... patient health, researchers have concluded. , A study ... avoid costs associated with insurance administration can help ... and emergency room visits, according to Mark Agee, ... The researchers estimated that the major hospital in ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... health care spending, a new RAND study concludes that ... pharmaceutical companies and device makers to develop products that ... technologies and their use, a new study suggests the ... devices get created in the first place. The aim ... little loss of health as possible and to ensure ...
(Date:4/22/2014)... of all patients diagnosed with non-small cell lung cancer ... this high percentage, these elderly patients are not well ... data has made it difficult to reach evidence based ... the Elderly Task Force and Lung Cancer Group along ... an expert opinion on managing treatment for elderly patients ...
(Date:4/22/2014)... but their total brain size suggests they have ... squirrel, according to a new study of 36 ... to zebra finches. , Scientists at Duke University, ... other research institutions collaborated on this first large-scale ... the study as the ability to inhibit powerful ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... 8 With rising food costs, many,families are economizing ... back,on is nutrition. At about 25 cents per 8-ounce ... penny than almost any other beverage option in the,supermarket ... vitamin D,that are important for the entire family. To ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... presenting at the upcoming 27th Annual J.P. Morgan Healthcare Conference. ... to begin on Wednesday, January 14, 2009 at 4:00 p.m. PT. ... Hotel in San Francisco, CAJanuary 11-15, 2009. , ...
... 8 Paul Spiegelman, author of Why Is ... knows a few things about how to infuse joy into ... from a proven track-record of success. Spiegelman,s commitment to creating ... the company he founded - The Beryl Companies - seven ...
... With its acclaimed debut in 2007,MyHealthArchive revolutionized every ... by bringing the process into the digital age. ... record-keeping, allowing,subscribers to take charge of their health ... under their own centralized control and energizing their ...
... 8 /PRNewswire-FirstCall/ - StonePoint Global Brands Inc. (TSXV:SPG) ... Oxford, has launched its upgraded in-room merchandising system ... packaging options, upgraded food selections, Room Service kits ... numerous other product and service improvements. , ...
... 8 Human Genome Sciences, Inc. (Nasdaq: HGSI ) ... results of ACHIEVE 2/3, its Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) , , The ... on Monday, December 8, 2008 at 8:15 am Eastern Time. , ...
Cached Medicine News:Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th 2Health News:'Smiling' Author Reveals 12 Ways To Make Your Workplace Merry This Holiday Season 2Health News:'Smiling' Author Reveals 12 Ways To Make Your Workplace Merry This Holiday Season 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 2Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 4Health News:StonePoint Announces Completion of Test Market and Launch of New Program 2Health News:Human Genome Sciences to Sponsor Conference Call 2
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
Graether Collar Button micro iris retractor....
Medicine Products: